Skip to main content

HOW CANCER DEVELOPES IN A NORMAL HUMAN BODY ??






Cancer
which is also known as Carcinoma. There are two terms regarding cancer and these are benign and malignant. Benign cancers are not fatal and these can be cured by treatment like surgery and radiotherapy. But malignant cancers are fatal. Because it can not be cured by treatment due to its spreading nature.

At first there are some stimuli that alters the normal function and growing pattern of a cell. The stimuli are called Carcinogens. Carcinogens are chemical or radiation or something like this. When carcinogens enter into the body repeatedly then it alters the normality of our cells. Then our cells show abnormality in growing and metabolism. At the same time our body tries to compensate this changes. But when fails then this abnormality takes figure into any benign lesion. This benign lesion can be the benign cancer cells in an adenoma ( Its a benign tumor of glandular tissue, like breast ) . Then these benign cells grows more rapidly due to repeated stimuli and finally spreads into other organs via blood streams or lymphatics. This is called metastasis. Metastasis can also occur by seeding through body cavities ( IE. Krukenbeg's Tumour of Overy ). Finally this spreader reside in another tissue of our body and further shows abnormality on that organ.

Now, What is the treatment of these things ? The ultimate goal to treat cancer is in two stages. Number one, is it in benign stage or in malignant stage. If its benign then we can treat it with a radiotherapy. Its nothing but a radioactive ray is given to destroy to those abnormal cells. But if its dissiminated through out the body then we will give the Chemotherapy. Its the chemical drugs that selectively destroyes those cancer cells. In benign stage we can also remove that mass of tumour by a surgery.

Comments

Popular posts from this blog

Monoclonal Antibody Targets, Kills Leukemia Cells

Monoclonal Antibody Targets, Kills Leukemia Cells  Researchers at the University of California, San Diego Moores Cancer Center have identified a humanized monoclonal antibody that targets and directly kills chronic lymphocytic leukemia (CLL) cells The findings, published in the online Early Edition of the Proceedings of the National Academy of Sciences on March 25, 2013 represent a potential new therapy for treating at least some patients with CLL, the most common type of blood cancer in the United States. CLL cells express high levels of a cell-surface glycoprotein receptor called CD44. Principal investigator Thomas Kipps, MD, PhD, Evelyn and Edwin Tasch Chair in Cancer Research, and colleagues identified a monoclonal antibody called RG7356 that specifically targeted CD44 and was directly toxic to cancer cells, but had little effect on normal B cells. Moreover, they found RG7356 induced CLL cells that expressed the protein ZAP-70 to undergo apoptosis or programmed cell death.

Stem Cell Treatment May Become Option to Treat Nonhealing Bone Fractures

Stem Cell Treatment May Become Option to Treat Non healing Bone Fractures Stem cell therapy enriched with a bone-regenerating hormone, insulin-like growth factor-I (IGF-I), can help mend broken bones in fractures that are not healing normally, a new animal study finds. The results are being presented at The Endocrine Society's 93rd Annual Meeting in Boston. A deficiency of fracture healing is a common problem affecting an estimated 600,000 people annually in North America, according to the principal investigator, Anna Spagnoli, MD, associate professor of pediatrics and biomedical engineering at the University of North Carolina at Chapel Hill. "This problem is even more serious," Spagnoli said, "in children with osteogenesis imperfecta, or brittle bone disease, and in elderly adults with osteoporosis, because their fragile bones can easily and repeatedly break, and bone graft surgical treatment is often not successful or feasible" Fractures that do not hea

Erythropoietin as a Retinal Angiogenic Factor in Proliferative Diabetic Retinopathy

Although vascular endothelial growth factor (VEGF) is a primary mediator of retinal angiogenesis, VEGF inhibition alone is insufficient to prevent retinal neovascularization. Hence, it is postulated that there are other potent ischemia-induced angiogenic factors. Erythropoietin possesses angiogenic activity, but its potential role in ocular angiogenesis is not established. METHODS We measured both erythropoietin and VEGF levels in the vitreous fluid of 144 patients with the use of radioimmunoassay and enzyme-linked immunosorbent assay. Vitreous proliferative potential was measured according to the growth of retinal endothelial cells in vitro and with soluble erythropoietin receptor. In addition, a murine model of ischemia-induced retinal neovascularization was used to evaluate erythropoietin expression and regulation in vivo. RESULTS The median vitreous erythropoietin level in 73 patients with proliferative diabetic retinopathy was significantly higher than that in 71 patients with